Skip to main content

Advertisement

Table 8 Efficacy or effectiveness of vaccination against human papillomavirus in males: anogenital lesions in participants who were seronegative and PCR-negative at enrolment

From: Efficacy, effectiveness and safety of vaccination against human papillomavirus in males: a systematic review

Study Design No. of events/no. of participants Unadjusted estimate (95% CI) Confounder-adjusted estimate (95% CI) VE (95% CI)
Vaccine Control
Condylomata acuminata
Genital
  Giuliano et al. (2011) [32]a RCT 3/2830.9 pyrs 28/2813.9 pyrs NR NA 89.4% (65.5–97.9%)
Anal
  Palefsky et al. (2011) [33]a RCT 0/386.8 pyrs 6/418.2 pyrs NR NA 100% (8.2–100%)
Anal intraepithelial neoplasia grade 2
 Palefsky et al. (2011) [33]a RCT 2/384.5 pyrs 9/418.6 pyrs NR NA 75.8% (−16.9 to 97.5%)
Anal intraepithelial neoplasia grade 3
 Palefsky et al. (2011) [33]a RCT 2/385.4 pyrs 6/419.7 pyrs NR NA 63.7 (−103 to 96.4%)
Anal cancer
 Palefsky et al. (2011) [33] RCT 0/386.8 pyrs 0/421.1 pyrs NR NA
Penile, perineal or perianal neoplasia grade 2 or 3
 Giuliano et al. (2011) [32]a RCT 0/2833.3 pyrs 1/2824.7 pyrs NR NA 100% (− 3788.2 to 100%)
Penile, perineal or perianal cancer
 Giuliano et al. (2011) [32] RCT 0/2833.3 pyrs 0/2826.2 pyrs NR NA
  1. NA not applicable, NR not reported, pyrs person-years, VE vaccine efficacy or effectiveness
  2. aVE as reported in the primary study